The corrected Nature Reviews 2026 primer delivers three essential clinical takeaways for practitioners managing atopic dermatitis. First, the sheer epidemiological scale demands recognition: 400 million individuals are affected globally, with 140 million experiencing moderate-to-severe disease requiring escalated therapeutic intervention beyond topical-only approaches. Second, the therapeutic landscape has fundamentally expanded. Clinicians now have access to biologic therapies and JAK inhibitors that complement traditional management, necessitating updated treatment algorithms and refined endotype classification strategies.
Third, and often overlooked, are the significant comorbidities extending beyond dermatology itself. Mental health disturbances and sleep disturbance represent major but underrecognised impacts requiring integrated multidisciplinary care. The updated primer emphasises that effective AD management must address psychological wellbeing and quality-of-life metrics alongside inflammatory skin control. These evidence-based insights should inform clinical decision-making and healthcare resource allocation for this high-burden chronic condition.
Read the full article on GMJ Newsroom.
Was this article helpful?
